Moomoo AI 已提取核心信息
On February 16, 2024, 180 Life Sciences Corp. filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated February 9, 2024. The supplement includes information from the company's Current Report on Form 8-K and announces shareholder approval for the issuance of shares upon exercise of certain warrants. The warrants are now exercisable until February 16, 2029. Additionally, at a Special Meeting on the same day, stockholders approved a reverse stock split, an amendment to the company's Omnibus Incentive Plan, and the issuance of shares exceeding 19.99% of the outstanding common stock at a price below the Nasdaq minimum. The company's common stock and warrants are traded on the Nasdaq under the symbols 'ATNF' and 'ATNFW' respectively. The last reported sale price of the common stock was $0.21 per share on February 15, 2024.
On February 16, 2024, 180 Life Sciences Corp. filed a prospectus supplement with the SEC, updating and amending its previous prospectus dated February 9, 2024. The supplement includes information from the company's Current Report on Form 8-K and announces shareholder approval for the issuance of shares upon exercise of certain warrants. The warrants are now exercisable until February 16, 2029. Additionally, at a Special Meeting on the same day, stockholders approved a reverse stock split, an amendment to the company's Omnibus Incentive Plan, and the issuance of shares exceeding 19.99% of the outstanding common stock at a price below the Nasdaq minimum. The company's common stock and warrants are traded on the Nasdaq under the symbols 'ATNF' and 'ATNFW' respectively. The last reported sale price of the common stock was $0.21 per share on February 15, 2024.
2024年2月16日，180生命科学公司向美国证券交易委员会提交了招股说明书补充文件，更新并修改了其先前于2024年2月9日发布的招股说明书。该补充文件包括公司8-K表最新报告中的信息，并宣布股东批准在行使某些认股权证后发行股票。认股权证现在的有效期至2029年2月16日。此外，在当天的特别会议上，股东批准了反向股票拆分、公司综合激励计划的修正案，以及以低于纳斯达克最低价格的价格发行超过已发行普通股19.99％的股票。该公司的普通股和认股权证分别在纳斯达克上市，股票代码分别为 “ATNF” 和 “ATNFW”。2024年2月15日，上次公布的普通股销售价格为每股0.21美元。
2024年2月16日，180生命科学公司向美国证券交易委员会提交了招股说明书补充文件，更新并修改了其先前于2024年2月9日发布的招股说明书。该补充文件包括公司8-K表最新报告中的信息，并宣布股东批准在行使某些认股权证后发行股票。认股权证现在的有效期至2029年2月16日。此外，在当天的特别会议上，股东批准了反向股票拆分、公司综合激励计划的修正案，以及以低于纳斯达克最低价格的价格发行超过已发行普通股19.99％的股票。该公司的普通股和认股权证分别在纳斯达克上市，股票代码分别为 “ATNF” 和 “ATNFW”。2024年2月15日，上次公布的普通股销售价格为每股0.21美元。
有用
没用
